[Infarct-related cardiogenic shock : Prognosis and treatment]

Area of Science:

• Cardiology
• Intensive Care Medicine

Background:

• Cardiogenic shock complicates ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) in 6-10% of cases.
• Incidence is decreasing due to advancements in invasive diagnostics and therapy post-myocardial infarction.

Purpose of the Study:

• To review current treatment strategies for cardiogenic shock complicating myocardial infarction.
• To highlight the importance of early diagnosis and revascularization.
• To discuss pharmacological and mechanical support options.

Main Methods:

• Review of current literature on cardiogenic shock management.
• Discussion of revascularization techniques like percutaneous coronary intervention (PCI).
• Overview of pharmacological agents (dobutamine, norepinephrine, levosimendan) and mechanical support (Impella, ECMO).

Main Results:

• Early PCI significantly improves survival rates in STEMI patients with cardiogenic shock.
• Pharmacological support involves inotropes and vasopressors; levosimendan offers additional support.
• Mechanical support systems like Impella and ECMO are vital, while IABP use has declined.
• Most survivors experience minimal long-term cardiac impairment, indicating transient damage.

Conclusions:

• Fast and effective cardiovascular supportive therapy is essential for cardiogenic shock survivors.
• Prompt diagnosis and revascularization are key to improving outcomes.
• A combination of pharmacological and mechanical support optimizes myocardial and organ perfusion.